Anthony Marucci
Gründer bei CELLDEX THERAPEUTICS, INC.
Vermögen: 1 Mio $ am 30.04.2024
Profil
Anthony S.
Marucci is the founder of Celldex Therapeutics, Inc., which was founded in 1983.
He holds the title of President, Chief Executive Officer & Director at Celldex Therapeutics, Inc. from 2008 to the present.
Currently, Mr. Marucci holds several positions.
He is the President, CEO, CFO, Secretary, Treasurer & VP at Celldex Research Corp.
since 2003.
He is also a Director at Celldex Therapeutics Ltd.
and an Independent Director at Genenta Science SpA since 2021.
Additionally, he serves as a Director at the College of Business & Public Management and as the President of CuraGen Corp.
He is a Trustee at BioNJ, Inc. since 2010.
In the past, Mr. Marucci served as the Interim President & Chief Executive Officer at AVANT Immunotherapeutics, Inc. in 2008.
He also held the position of Treasurer & Acting Chief Executive Officer at Celldex Therapeutics, Inc. (Old).
From 1998 to 2004, he was the Treasurer at Medarex, Inc.Mr. Marucci's education history includes a graduate degree from Brown University, an MBA from The Trustees of Columbia University in The City of New York, and an undergraduate degree from Kean University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 05.04.2024 | 28 550 ( 0,04% ) | 1 Mio $ | 30.04.2024 | |
GENENTA SCIENCE SPA
0,12% | 19.04.2023 | 21 233 ( 0,12% ) | 61 873 $ | 30.04.2024 |
Aktive Positionen von Anthony Marucci
| Unternehmen | Position | Beginn |
|---|---|---|
| CELLDEX THERAPEUTICS, INC. | Gründer | 01.01.1983 |
| GENENTA SCIENCE S.P.A. | Direktor/Vorstandsmitglied | 20.05.2021 |
BioNJ, Inc.
 BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart. | Direktor/Vorstandsmitglied | 01.01.2010 |
| Celldex Therapeutics Ltd. | Direktor/Vorstandsmitglied | 06.08.2010 |
Celldex Research Corp.
 Celldex Research Corp. Miscellaneous Commercial ServicesCommercial Services Celldex Research Corp. engages in provision of biological research and development. The company is headquartered in Phillipsburg, NJ. | Vorstandsvorsitzender | 01.05.2003 |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Präsident | - |
| College of Business & Public Management | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Anthony Marucci
| Unternehmen | Position | Ende |
|---|---|---|
AVANT Immunotherapeutics, Inc.
 AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Präsident | 01.10.2008 |
Medarex, Inc.
 Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Treasurer | 01.03.2004 |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░ | ░░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Anthony Marucci
| Brown University | Graduate Degree |
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| Kean University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CELLDEX THERAPEUTICS, INC. | Health Services |
| GENENTA SCIENCE S.P.A. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Commercial Services |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Health Technology |
Celldex Therapeutics, Inc. (Old)
 Celldex Therapeutics, Inc. (Old) BiotechnologyHealth Technology Celldex Therapeutics, Inc. discovers, develops and commercialized novel immunotherapeutics. It offers treatment for cancer, infectious diseased and immune system disorders. The company was founded in May, 2003 and is headquartered in Philipsburg, NJ. | Health Technology |
BioNJ, Inc.
BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart. | Commercial Services |
Celldex Research Corp.
Celldex Research Corp. Miscellaneous Commercial ServicesCommercial Services Celldex Research Corp. engages in provision of biological research and development. The company is headquartered in Phillipsburg, NJ. | Commercial Services |
| Celldex Therapeutics Ltd. | |
| College of Business & Public Management |
